China Universal Asset Management Company’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

China Universal Asset Management Company’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-334	Closed	-$5.27K	–	490
2023 Q3	$5.27K	Buy	334 +162	+94%	+$2.91K	﹤0.01%	387
2023 Q2	$3.34K	Sell	172 -5	-3%	-$119	﹤0.01%	404
2023 Q1	$5.02K	Buy	177 +45	+34%	+$1.34K	﹤0.01%	366
2022 Q4	$3.86K	Buy	132 +8	+6%	+$254	﹤0.01%	327
2022 Q3	$3K	Buy	+124	New	+$4.55K	﹤0.01%	340

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

China Universal Asset Management Company's EGRX Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 334 shares — an estimated $5.27K sold.

China Universal Asset Management Company first reported a position in EGRX in Q3 2022 and held it in 5 quarters. The position peaked at $5.27K in Q3 2023. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

China Universal Asset Management Company reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 334 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $5.27K.
China Universal Asset Management Company first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Eagle Pharmaceuticals, Inc. position peaked at $5.27K in Q3 2023.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.